Cefoperazone/Sulbactam: Extended coverage with β-lactamase inhibition
Example
Adapted from Lai CC, et al. 2018.
The synergistic in vitro antibacterial activity of the cefoperazone + sulbactam combination results in lower MICs compared with cefoperazone alone for a wide range of pathogens.
Cefoperazone/Sulbactam enhances cefoperazone activity against most MDROs excluding carbapenem-resistant P. aeruginosa, and the activity is greatest at a ratio of 1:2, followed by ratios of 1:1 and 2:1.2
ESBL, extended-spectrum β-lactamase; MDRO, multidrug-resistant organism; MIC, minimum inhibitory concentration.
References:
Please click the Prescribing Information link to view the safety and adverse events information of MAGNEX®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.